论文部分内容阅读
目的:探讨中药联合恩替卡韦治疗乙肝后肝硬化患者血清ALT、AST以及AST/ALT的变化。方法:2013年1月—2014年1月,我院收治乙肝肝硬化患者80例,随机分为观察组和对照组。其中观察组采用中药方剂联合恩替卡韦治疗,对照组患者采用恩替卡韦治疗。治疗3、6以及12个月后,观察两组患者血清丙氨酸氨基转移酶(ALT)、天冬氨酸转氨酶(AST)以及AST/ALT的变化。结果:治疗3个月后观察组患者ALT和AST分别为(114.35±21.39)U/L和(123.76±29.45)U/L,而对照组患者ALT和AST分别为(169.47±24.46)U/L和(192.36±32.13)U/L,比较差异有统计学意义(P<0.05)。治疗6个月后观察组患者ALT和AST分别为(63.17±17.08)U/L和(83.42±12.95)U/L,而对照组患者ALT和AST分别为(109.57±15.03)U/L和(112.84±16.03)U/L,比较差异有统计学意义(P<0.05)。治疗12月后观察组患者ALT和AST分别为(24.47±6.09)U/L和(33.08±3.59)U/L,而对照组患者ALT和AST分别为(59.31±5.42)U/L和(62.05±4.12)U/L,比较差异有统计学意义(P<0.05)。而ALT/AST的比较,差异无统计学意义(P>0.05)。结论:护肝散结中药方剂联合恩替卡韦治疗乙肝肝硬化患者,可以明显改善患者血清ALT和AST指标,并且比单纯使用恩替卡韦起效快,改善肝功能效果更加明显。在乙肝肝硬化的临床治疗过程中,应当重视我国传统医学,注重中西医结合,可以取得更好的治疗效果。
Objective: To investigate the changes of serum ALT, AST and AST / ALT in patients with posthepatitic cirrhosis treated with traditional Chinese medicine and entecavir. Methods: From January 2013 to January 2014, 80 patients with hepatitis B cirrhosis were randomly divided into observation group and control group. The observation group was treated with traditional Chinese medicine prescription and entecavir, and the control group was treated with entecavir. At 3, 6 and 12 months after treatment, the changes of serum ALT, AST and AST / ALT were observed in both groups. Results: The ALT and AST in observation group were (114.35 ± 21.39) U / L and (123.76 ± 29.45) U / L respectively after 3 months of treatment, while those in control group were (169.47 ± 24.46) U / L And (192.36 ± 32.13) U / L, the difference was statistically significant (P <0.05). The ALT and AST in observation group were (63.17 ± 17.08) U / L and (83.42 ± 12.95) U / L respectively after 6 months of treatment, while those in control group were (109.57 ± 15.03) U / L and 112.84 ± 16.03) U / L, the difference was statistically significant (P <0.05). The ALT and AST in the observation group were (24.47 ± 6.09) U / L and (33.08 ± 3.59) U / L respectively after 12 months of treatment, while those in the control group were (59.31 ± 5.42) U / L and ± 4.12) U / L, the difference was statistically significant (P <0.05). The ALT / AST comparison, the difference was not statistically significant (P> 0.05). Conclusion: Hugan Sanjie combined with entecavir treatment of patients with hepatitis B cirrhosis can significantly improve the serum ALT and AST indicators, and the effect than the simple use of entecavir fast onset and improve liver function more obvious. In the clinical treatment of hepatitis B cirrhosis, we should attach importance to traditional Chinese medicine, focusing on the combination of Chinese and Western medicine, can achieve better therapeutic effect.